[go: up one dir, main page]

TN2009000004A1 - Compositions and methods for the treatment of mucormycosis and other fungal diseases - Google Patents

Compositions and methods for the treatment of mucormycosis and other fungal diseases

Info

Publication number
TN2009000004A1
TN2009000004A1 TN2009000004A TN2009000004A TN2009000004A1 TN 2009000004 A1 TN2009000004 A1 TN 2009000004A1 TN 2009000004 A TN2009000004 A TN 2009000004A TN 2009000004 A TN2009000004 A TN 2009000004A TN 2009000004 A1 TN2009000004 A1 TN 2009000004A1
Authority
TN
Tunisia
Prior art keywords
antifungal agent
iron chelating
fungal condition
chelating compound
fungal
Prior art date
Application number
TN2009000004A
Other languages
French (fr)
Inventor
Brad J Spellberg
John E Edwards
Ashraf S Ibrahim
Original Assignee
Los Angeles Biomed Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomed Res Inst filed Critical Los Angeles Biomed Res Inst
Publication of TN2009000004A1 publication Critical patent/TN2009000004A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a composition including at least one iron chelating compound and at least one antifungal agent. The composition can include the iron chelating compounds deferiprone or deferasirox. An antifungal agent included in the composition can include a polyene antifungal agent, an azole antifungal agent or an echinocandin antifungal agent.. The invention also provides a method of treating or preventing a fungal condition. The method includes administering to an individual having or susceptible to having. a fungal condition a therapeutically effective amount of at least one iron chelating compound for a sufficient time to reduce the severity of a fungal condition, wherein the iron chelating compound comprises a non-siderophore or non-xenosiderophore relative to the fungal condition. A method of treating or preventing a fungal condition provided by the invention also can include administering to an individual having, or susceptible of having, a fungal condition a therapeutically effective amount of at least one iron chelating compound and at least one antifungal agent.. Provided further by the invention is a method including prophylactic administration of the at least one iron chelating compound or at least one iron chelating compound and at least one antifungal agent prior to onset of the fungal condition.
TN2009000004A 2006-07-13 2009-01-12 Compositions and methods for the treatment of mucormycosis and other fungal diseases TN2009000004A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83109906P 2006-07-13 2006-07-13
US89762007P 2007-01-26 2007-01-26
US90407507P 2007-02-27 2007-02-27
PCT/US2007/016065 WO2008008537A2 (en) 2006-07-13 2007-07-13 Combi) compositions for the treatment of mucormycosis. comprising iron chelator and antifungal agent

Publications (1)

Publication Number Publication Date
TN2009000004A1 true TN2009000004A1 (en) 2010-08-19

Family

ID=38610625

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000004A TN2009000004A1 (en) 2006-07-13 2009-01-12 Compositions and methods for the treatment of mucormycosis and other fungal diseases

Country Status (18)

Country Link
US (1) US20100129434A1 (en)
EP (2) EP2412371A1 (en)
JP (2) JP2009543788A (en)
KR (1) KR20090036587A (en)
AU (1) AU2007272781B2 (en)
BR (1) BRPI0714221A2 (en)
CA (1) CA2657634A1 (en)
CL (1) CL2007002026A1 (en)
IL (1) IL196389A0 (en)
MA (1) MA30625B1 (en)
MX (1) MX2009000506A (en)
NO (1) NO20090565L (en)
NZ (1) NZ574862A (en)
RU (1) RU2464024C2 (en)
SG (1) SG177122A1 (en)
TN (1) TN2009000004A1 (en)
TW (1) TWI448285B (en)
WO (1) WO2008008537A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444985B2 (en) * 2009-03-19 2013-05-21 Los Angeles Biomedical Research Institute at Harbor-ULCA Medical Center Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
US8980876B2 (en) 2010-10-28 2015-03-17 The Procter & Gamble Company Inhibition of microbial growth by aconitase inhibition
BR112015006641A2 (en) * 2012-11-12 2017-07-04 Cipla Ltd fixed dose pharmaceutical composition, use of a fixed dose pharmaceutical composition, method for treating chronic iron overload and process for preparing a fixed dose pharmaceutical composition
WO2014120774A1 (en) 2013-01-29 2014-08-07 Case Western Reserve University Fungal iron acquisition inhibitors and uses thereof
WO2015026852A1 (en) * 2013-08-19 2015-02-26 Rutgers, The State University Of New Jersey Method of inducing an anti-retroviral immune response by counter-acting retro-virus induced anti-apoptosis
WO2016025611A2 (en) * 2014-08-13 2016-02-18 Zoneone Pharma, Inc. Pharmaceutical formulations of chelating agents as a metal removal treatment system
US20170239182A1 (en) * 2014-08-13 2017-08-24 Mark E. Hayes Pharmaceutical formulations of and methods to prepare chelating agents for efficient metal removal treatment systems
JP2018528207A (en) * 2015-08-31 2018-09-27 ザ ユニバーシティー オブ アデレード Methods and products for preventing and / or treating microbial infections comprising iron chelators and non-ferrous porphyrins
US10960002B2 (en) 2016-05-13 2021-03-30 The Brigham And Women's Hospital, Inc. Volatile metabolite profiles for the diagnosis and treatment of Mucorales fungi
FR3095755A1 (en) * 2019-05-10 2020-11-13 Balmes Transplantation New cytoprotective drugs
WO2020264076A1 (en) 2019-06-28 2020-12-30 The Procter & Gamble Company Light augmented treatment method

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8329043D0 (en) * 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
WO1999009997A1 (en) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
EP1223308B1 (en) * 2000-12-16 2007-01-24 ALSTOM Technology Ltd Turbomachine component
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
ITMI20022447A1 (en) * 2002-11-19 2004-05-20 Carlo Ghisalberti USE OF PYRIDINONS IN THE TREATMENT OF CAPILLARY PURPURE AND RELATED SKIN DISEASES.
MXPA05007156A (en) * 2002-12-31 2005-09-21 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy.
WO2004108114A2 (en) * 2003-03-31 2004-12-16 Dinesh Shantilal Patel Anti-fungal composition and a process for its manufacture
DE10356409B4 (en) * 2003-11-28 2006-12-28 Biofrontera Discovery Gmbh New drug oxacheline and derivatives

Also Published As

Publication number Publication date
US20100129434A1 (en) 2010-05-27
IL196389A0 (en) 2009-09-22
AU2007272781A1 (en) 2008-01-17
WO2008008537A2 (en) 2008-01-17
BRPI0714221A2 (en) 2013-01-01
RU2009104961A (en) 2010-08-20
NO20090565L (en) 2009-03-30
KR20090036587A (en) 2009-04-14
RU2464024C2 (en) 2012-10-20
JP2009543788A (en) 2009-12-10
TWI448285B (en) 2014-08-11
NZ574862A (en) 2012-02-24
WO2008008537A3 (en) 2008-04-24
MX2009000506A (en) 2009-05-20
MA30625B1 (en) 2009-08-03
JP2013040212A (en) 2013-02-28
SG177122A1 (en) 2012-01-30
AU2007272781B2 (en) 2012-10-18
EP2412371A1 (en) 2012-02-01
TW200816994A (en) 2008-04-16
CL2007002026A1 (en) 2008-06-06
CA2657634A1 (en) 2008-01-17
EP2043636A2 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
TN2009000004A1 (en) Compositions and methods for the treatment of mucormycosis and other fungal diseases
NZ597489A (en) Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2008050329A3 (en) Novel sirnas and methods of use thereof
MX2007009649A (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer.
WO2007128526A3 (en) Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases
WO2011047439A8 (en) Novel parasite therapy
WO2007112000A3 (en) Treatment of pain
MX2010007584A (en) Protein kinase inhibitors and use thereof.
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
MX2009005649A (en) Treatment for multiple myeloma.
MX2019011506A (en) Combinations of chk1- and wee1 - inhibitors.
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
MX2022009197A (en) Methods of treatment for alpha-1 antitrypsin deficiency.
TW200639159A (en) Treatment of pain
WO2008077062A3 (en) Suppression of stat3 reactivation after src kinase inhibition to treat cancer
EA200800766A1 (en) PI3K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS
TW200742580A (en) Methods for treating nephrolithiasis
WO2007015841A3 (en) A method for treating preeclampsia
WO2002055022A3 (en) Active metabolite of antifungal compound
WO2007136615A3 (en) Combination cancer therapy
NO20035038D0 (en) Prevention of addiction to pain management
WO2008016665A3 (en) Imidazoacridine compounds for treating flt3 -mediated disorders
WO2006101909A3 (en) Combination therapy for treating or preventing diseases
TNSN08479A1 (en) Method of treatment of hereditary hemochromatosis